Cromwell may be growing too fast for Mums and Dads.
Hard on the heels of its Box Hill trust offer came an
offer to invest over $400 million in former NSW
office blocks, then two Brisbane office blocks.
The retail offer to invest in the NSW office blocks
at $1 per share followed an institutional offer
to invest at the same $1 per share. But the
market in hi-yield shares plunged after
Americans regained faith in US shares.
Why buy CMW (via the retail offer) at $1 each when
Mums and Dads could buy at 97 cents on the ASX
Underwriters are being allocated (at $1) the
47.6 million shortfall in CMW securities.
My wife and I also sat out the retail offer.
- Forums
- ASX - By Stock
- CMW
- cromwell's retail offer gets few takers
cromwell's retail offer gets few takers
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
BOE
Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
NEWS
Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo
Add CMW (ASX) to my watchlist
|
|||||
Last
42.0¢ |
Change
0.010(2.44%) |
Mkt cap ! $1.099B |
Open | High | Low | Value | Volume |
41.5¢ | 42.0¢ | 41.0¢ | $834.5K | 1.989M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 41.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
42.0¢ | 63242 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.415 |
2 | 101979 | 0.410 |
2 | 57200 | 0.405 |
2 | 1000 | 0.400 |
4 | 126271 | 0.395 |
Price($) | Vol. | No. |
---|---|---|
0.420 | 63242 | 2 |
0.425 | 100050 | 6 |
0.430 | 43123 | 4 |
0.435 | 159460 | 5 |
0.440 | 25446 | 3 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
BOE
Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
CMW (ASX) Chart |